CTLA4 and cancer: Immune checkpoint blockade (ICB), particularly targeting CTLA-4 or PD-1/PD-L1, has significantly advanced cancer treatment, offering clinical benefits across various cancers, including melanoma, NSCLC, and renal cell carcinoma [204,205,206,207].